Theravance Biopharma (TBPH) to Release Earnings on Monday

Theravance Biopharma (NASDAQ:TBPH) will likely be posting its quarterly earnings results after the market closes on Monday, February 24th. Analysts expect Theravance Biopharma to post earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $9.61 on Monday. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $10.90. The company’s fifty day moving average is $9.44 and its two-hundred day moving average is $8.88. The stock has a market capitalization of $472.52 million, a price-to-earnings ratio of -9.51 and a beta of 0.21.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.